Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders
- 399 Downloads
We investigated the plasma levels of VEGF and FGF-2, important factors for regulation of neuroplasticity such as neurogenesis, in patients in remission from major depressive disorders (MDD). The plasma VEGF levels were significantly higher in the MDD patients than in the matched control subjects, while no significant difference in plasma FGF-2 levels was found. In particular, the MDD patients with family history of psychiatric disorders, but not patients without such a family history, showed significantly higher values of plasma VEGF than the controls. Although this is a preliminary study, altered VEGF levels might be involved in the pathophysiology of MDD.
KeywordsVEGF FGF-2 Plasma Family history Mood disorders
This study was supported by the Research Grants for Nervous and Mental Disorders from the NCNP, Health and Labor Sciences Research Grants (Research on Psychiatric and Neurological Diseases and Mental Health), a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (JSPS), and JST, CREST.
- American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Press, Washington, DCGoogle Scholar
- Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H, Lopez JF, Thompson RC, Meng F, Stead JD, Walsh DM, Myers RM, Bunney WE, Watson SJ, Jones EG, Akil H (2004) Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 101(43):15506–15511CrossRefPubMedGoogle Scholar
- Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, Nakataki M, Song H, Hokoishi K, Tanabe H, Sano A, Ohmori T (2007) Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 31(3):658–663CrossRefPubMedGoogle Scholar
- Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, Nakazato M, Watanabe H, Shinoda N, Okada S, Iyo M (2003) Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry 54(1):70–75CrossRefPubMedGoogle Scholar
- Takebayashi M, Hisaoka K, Nishida A, Tsuchioka M, Miyoshi I, Kozuru T, Hikasa S, Okamoto Y, Shinno H, Morinobu S, Yamawaki S (2006) Decreased levels of whole blood glial cell line-derived neurotrophic factor (GDNF) in remitted patients with mood disorders. Int J Neuropsychopharmacol 9(5):607–612CrossRefPubMedGoogle Scholar
- Takebayashi M, Hisaoka K, Tsuchioka M (2009) Glial dysfunction in mood disorders: the role of GDNF. In: Shirayama Y, Chaki S (eds) Recent developments on depression research. Research Signpost, Kerala, pp 125–143Google Scholar
- Tsai SJ, Hong CJ, Liou YJ, Chen TJ, Chen ML, Hou SJ, Yen FC, Yu YW (2009) Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder. Psychiatry Res 169(2):113–117CrossRefPubMedGoogle Scholar